The use of a contraceptive vaginal ring governed by the pattern of individual uterine bleeding
- PMID: 455988
- DOI: 10.1016/0010-7824(79)90034-9
The use of a contraceptive vaginal ring governed by the pattern of individual uterine bleeding
Abstract
Contraceptive vaginal rings (CVR) releasing levonorgestrel and estradiol were used for contraceptive purposes in eight women. They were instructed to remove the CVR for five days only, in the case of bleeding. Three selected subjects were followed by plasma sampling during the first 60 days of treatment. Plasma concentrations of levonorgestrel, progesterone, estradiol and gonadotropins were determined. All subjects kept bleeding records and were controlled clinically in the course of treatment. The subjects were protected an average of 163 days by the CVR. Three subjects used the CVR 170--180 days without removing it and two subjects had to remove the CVR only once. Two subjects experienced quite regular bleedings, and metrorrhagic bleeding was present in one case. No pregnancies were observed during the follow-up period of 1304 days. Clinical examination revealed no pathological findings. The vaginal mucosa tolerated the treatment well. Out of those subjects who were followed by plasma sampling, pituitary suppression was more marked in the subject with continuous use of CVR.
PIP: In the attempt clinically to evaluate the bleeding signaled method for the levonorgestrel and estradiol contraceptive vaginal ring (CVR), the patient acceptance, the bleeding pattern, and the local tolerance of long-lasting continuous use of the CVR, endocrine parameters in selected patients were determined by measuring plasma levonorgestrel, estradiol, progesterone, LH and FSH concentrations. The CVR were used for contraceptive purposes in 8 women who were instructed to remove the CVR for 5 days only, in the case of bleeding. 3 selected subjects were followed by plasma sampling during the first 60 days of treatment. All subjects kept bleeding records and were controlled clinically in the course of treatment. The subjects were protected an average of 163 days by the CVR. 3 subjects used the CVR 170-180 days without removing it and 2 subjects had to remove the CVR only once. 2 subjects experienced quite regular bleedings, and metrorrhagic bleeding was present in 1 cases. There were no pregnancies during the 1304 days follow-up. Clinical examination showed no pathological findings. The vaginal mucosa tolerated the treatment well. In the subjects followed by plasma sampling, pituitary suppression was more marked in the subject with continuous CVR use.
Similar articles
-
Bleeding and ovulation control with use of a small contraceptive vaginal ring releasing levonorgestrel and estradiol.Contraception. 1979 Jul;20(1):11-8. doi: 10.1016/0010-7824(79)90040-4. Contraception. 1979. PMID: 477313
-
Intravaginal contraception with the synthetic progestin, R2010.Contraception. 1979 Nov;20(5):511-8. doi: 10.1016/0010-7824(79)90056-8. Contraception. 1979. PMID: 527342
-
Levonorgestrel plasma concentrations and hormone profiles after insertion and after one year of treatment with a levonorgestrel-IUD.Contraception. 1980 Mar;21(3):225-33. doi: 10.1016/0010-7824(80)90003-7. Contraception. 1980. PMID: 6771090
-
Safety, efficacy and quality of life of the novel vaginal contraceptive ring containing etonogestrel/ethinylestradiol 11.0/3.474 mg after 3 years of "real life" experience.Eur Rev Med Pharmacol Sci. 2020 Nov;24(22):11810-11819. doi: 10.26355/eurrev_202011_23838. Eur Rev Med Pharmacol Sci. 2020. PMID: 33275253 Review.
-
Vaginal contraceptive rings.Ann Med. 1993 Apr;25(2):191-7. doi: 10.3109/07853899309164167. Ann Med. 1993. PMID: 8489760 Review.
Cited by
-
Controlled-release delivery systems for hormones. A review of their properties and current therapeutic use.Drugs. 1984 Jun;27(6):528-47. doi: 10.2165/00003495-198427060-00002. Drugs. 1984. PMID: 6376061 Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources